21 Jun 2017 11:55
Cathay International Holdings Limited
("Cathay" or the "Company")
Results of Annual General Meeting ("AGM")
Hong Kong, 21 June 2017 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China, today announces that at the AGM held earlier today, all resolutions as set out in the Notice of AGM dated 28 April 2017 were duly passed, save for ordinary resolutions numbered 2 and 3 (the "Re-Election Resolutions") which are subject to the dual voting requirements of Listing Rule 9.2.2E. Although the Re-Election Resolutions were approved by a majority of all shareholders, the majority of the votes cast by the independent shareholders were against the Re-Election Resolutions. Accordingly, and pursuant to Listing Rule 9.2.2F, further ordinary resolutions to re-elect the respective directors (Messrs Sum Soon Lim and Kenneth K. Toong) (the "Further Re-Election Resolutions") will be proposed by the Company. The relevant voting will take place on a date to be announced by the Company within a period commencing 90 days from today's date and ending 120 days from today's date. Pursuant to the guidance note at Listing Rule 9.2.2D, Messrs Sum Soon Lim and Kenneth K. Toong shall remain in office until the Further Re-Election Resolutions have been voted upon by all shareholders of the Company. Pursuant to Listing Rule 9.2.2F(3), the Further Re-Election Resolutions must be approved by the shareholders of the Company, without the requirement for separate voting by the independent shareholders. The final poll voting results for each resolution are shown in the table below:
Ordinary resolutions | For | Against | Total votes | Withheld |
1. Report and Accounts | 396,219,499 | 41,723,364 | 437,942,863 | 5,256 |
2. Re-election of Mr. Sum Soon Lim | ||||
- all shareholders | 396,217,937 | 41,728,282 | 437,946,219 | 1,900 |
- independent shareholders | 6,075,983 | 41,728,282 | 47,804,265 | 1,900 |
3. Re-election of Mr. Kenneth K. Toong | ||||
- all shareholders | 396,219,887 | 41,726,332 | 437,946,219 | 1,900 |
- independent shareholders | 6,077,933 | 41,726,332 | 47,804,265 | 1,900 |
4. Reappointment of Auditor | 437,804,293 | 141,926 | 437,946,219 | 1,900 |
5. Authority to allot new shares | 437,806,260 | 139,959 | 437,946,219 | 1,900 |
Special resolutions | For | Against | Total votes | Withheld |
6. Disapplication of pre-emption rights | 396,196,609 | 41,744,610 | 437,941,219 | 6,900 |
7. Authority to purchase own shares | 437,943,080 | 5,039 | 437,948,119 | 0 |
Notes:
1. Any proxy votes which are at the discretion of the Chairman have been included in the 'For' total.
2. A vote 'Withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes for and against a resolution.
A copy of the resolutions passed at the meeting is being uploaded today to the National Storage Mechanism and will shortly be available for viewing at www.morningstar.com.
The proxy figures for the resolutions will also be displayed on the Company website at www.cathay-intl.com.hk
- ENDS -
For further enquiries, please contact:
Cathay International Holdings Limited Eric Siu (Finance Director) Patrick Sung (Director and Controller)
|
Tel: +852 2828 9289 |
Consilium Strategic Communications Mary-Jane Elliott / Matthew Neal / Lindsey Neville
|
Tel: +44 (0) 203 709 5702
|
About Cathay
Cathay International Holdings Limited (LSE: CTI.L) is a main market listed investment holding company and an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"). The Company and its subsidiaries (collectively the "Group") aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in the PRC and build its portfolio companies into market sector leaders with competitive edge. Cathay has already demonstrated a strong track record of identifying high- growth potential investment opportunities in this area including: Lansen, a leading specialty pharmaceutical company focused on rheumatology and dermatology in the PRC; Haizi, a company engaged in the manufacture, marketing and sale of inositol and its by-product, di-calcium phosphate; Natural Dailyhealth, a company engaged in production and sales of plant extracts for use as key active ingredients in healthcare products; and Botai, a company engaged in collagen products.
The Group employs approximately 2,000 people across the PRC, including over 30 specialist corporate and business development staff based at the holding company's offices in Hong Kong and Shenzhen. Cathay also has a hotel investment. For more information please visit the Company's website: www.cathay-intl.com.hk.